General Information
Sorafenib Impurities and Sorafenib
Daicel Pharma is a reliable source for synthesizing high-quality Sorafenib impurities, N-Desmethyl Sorafenib, Sorafenib dimethyl ester dimer impurity, Sorafenib Impurity 6, Sorafenib impurity 8, Sorafenib N-Oxide, Sorafenib Impurity-B, Sorafenib Impurity-D, Sorafenib Impurity-E, etc. These impurities are essential in analyzing the active pharmaceutical ingredient Sorafenib’s quality, stability, and biological safety. Additionally, Daicel Pharma specializes in the custom synthesis of Sorafenib impurities, catering to specific client requirements. These high-quality impurities can be shipped globally, offering convenience and flexibility to customers worldwide.
Sorafenib [CAS: 284461-73-0] treats unresectable hepatocellular carcinoma and advanced renal cell carcinoma in patients who have not responded to previous interferon-alpha or interleukin-2-based therapy or are deemed unsuitable for such treatment.
Sorafenib: Use and Commercial Availability
Sorafenib is a versatile medication with multiple indications. It primarily treats hepatocellular carcinoma, a form of liver cancer. Additionally, Sorafenib is for patients with advanced renal cell carcinoma who have not responded to prior interferon-alpha or interleukin-2-based therapy or are deemed unsuitable for such treatment. Furthermore, it is approved for treats progressive, locally advanced, or metastatic, differentiated thyroid carcinoma that does not respond to radioactive iodine therapy. Sorafenib’s wide range of applications makes it a valuable option for patients with different types of cancer.
Sorafenib is available under Nexavar, which contains the active ingredient, Sorafenib.
Sorafenib Structure and Mechanism of Action 
The chemical name of Sorafenib is 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide. Its chemical formula is C21H16ClF3N4O3, and its molecular weight is approximately 464.8 g/mol.
Sorafenib inhibits tumor growth of murine renal cell carcinoma.
Sorafenib Impurities and Synthesis
During Sorafenib’s manufacturing1, impurity formation is possible, compromising its effectiveness. They can arise from various sources, including the raw materials, intermediates, and chemicals utilized to synthesize Sorafenib. Closely managing and monitoring these impurities is paramount to ensure the drug’s optimal efficacy and safety.
Daicel offers a Certificate of Analysis (CoA) for Sorafenib impurity standards, encompassing N-Desmethyl Sorafenib, Sorafenib dimethyl ester dimer impurity, Sorafenib Impurity 6, Sorafenib impurity 8, Sorafenib N-Oxide, Sorafenib Impurity-B, Sorafenib Impurity-D, Sorafenib Impurity-E, etc. The CoA provides detailed characterization data, including 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. Additionally, we give a detailed 13C-DEPT on delivery. With advanced technology and expertise, Daicel can synthesize any unknown Sorafenib impurity or degradation product. We also supply labeled compounds, facilitating the quantification of generic Sorafenib’s efficacy. For bioanalytical research and BA/BE studies, we also offer deuterium-labeled Sorafenib standard Sorafenib D3.